C-Z3MEAltoida
neuroscience, machine learning, sensor data
diagnostics
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-Z3ME
C-Z3MEC-Z3MEneuroscience, machine learning, sensor data
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The company presents the view that cognitive decline can be detected earlier and more objectively by measuring real-world functional behavior through augmented-reality and sensor-based tasks on mobile devices, instead of relying only on traditional clinical assessments. Its stated belief is that these digital biomarkers can reveal subtle changes associated with mild cognitive impairment and Alzheimer's disease and support earlier monitoring and intervention.
SourceAltoida states that Alzheimer's disease can be diagnosed as early as five years before onset by measuring neuromotor biomarkers through complex everyday activities performed on smartphones with augmented reality, and that earlier detection would materially improve treatment, therapy, and quality years before symptoms appear. The company also argues that diagnosis should become cheaper and more scalable than clinic-based methods, and that prevention or treatment should be personalized using individual biological and lifestyle factors rather than one-size-fits-all approaches.
SourceNo company beliefs, mission statement, or theory claims are visible in the provided January 2, 2018 Wayback snapshot text; the visible content consists only of Internet Archive navigation and collection metadata rather than Altoida's site content.
Source